2012

FOUNDING OF LABORATOIRES MAJORELLE
2012

Laboratoires Majorelle’s history began in 2012, a year marked by the contraceptive pill crisis in France.

The 3rd generation contraceptive pill was the focus of a great deal of media attention related to the risk of venous thrombosis, which was becoming a true public health problem.

With its expertise and an approach based on the experiences of patients and the assistance provided to them, Laboratoires Majorelle developed a new range of contraceptive pills that were unlike any others on the market. Majorelle contraceptive pills are taken continuously over a 28-day cycle to make it easier for women to adhere to the regimen without fail. Optilova1,2 and Optidril1,2 are the next generation of contraceptive pills reimbursed by social security.

1 Avis de la Commission de la Transparence Optilova – Optidril

2 Document d’aide à la prescription

2014

LAUNCH OF THE FIRST PROGESTOGEN-ONLY PILL REIMBURSED BY SOCIAL SECURITY (OPTIMIZETTE)
2014

Driven by the aim of making the best treatment available to as many people as possible, Laboratoires Majorelle launched the first progestogen-only pill that is reimbursed by social security: Optimizette1, which rounds out the Opti range.

Because they are reimbursed by social security, Laboratoires Majorelle has been able to make progestogen-only pills available to over 1.1 million women, thereby preventing 790 cases of venous thrombosis per year.

1Avis de la Commission de la Transparence Optimizette

2015

LAUNCH OF THE FIRST TOPICAL ERECTILE DYSFONCTION TREATMENT
2015

Majorelle has launched the first topical erectile dysfunction treatment (Vitaros1,2), thereby becoming a key player in sexology.

1 Avis de la Commission de la Transparence Vitaros

2 Fiche d’Information Thérapeutique Vitaros

2016

LABORATOIRES MAJORELLE IS BECOMING A LEADER IN CONTRACEPTION, LAUNCHING LEVOSOLO, A MORNING-AFTER PILL
2016

Thanks to its commitment in the area of contraception, Laboratoires Majorelle is becoming a leader in this market. The Opti range has played a large part in reducing the available share of pills with a venous thrombosis risk.

1 Summary of Product Characteristics – Levosolo

2017

BLADDER LEAKAGE PREVENTION MEDIA CAMPAIGN
2017

Laboratoires Majorelle is committed to reducing bladder leakage, a condition that currently affects 9 million women in France and is a taboo, shame-generating topic. It is launching a prevention campaign in the media to offer solutions such as KEAT, a medical device that can be used at home to treat bladder leakage. It is the leading product of its kind of the market.

2018

MAJORELLE PURSUES ITS GROWTH AND STRENGHTEN ITS POSITION AS A FRENCH KEY ACTOR PHARMACEUTICAL COMPANY
2018

2018 is a new step in the development of its health and wellness activities:

– Launch of Eden, the first and the only one reimbursed,

– Launch of Etoring1, hormonal birth control ring for women

– Acquisition of Maternov, first range exclusively dedicated to pregnancy

– Acquisition of Assanis, first range of hydroalcoholic gels in France

1 Document d’aide à la prescription